Phase II trials of 5-fluorouracil and leucovorin in patients with metastatic gastric or pancreatic carcinoma

Cancer

Volumn 78, Issue 9, 1996, Pages 1888-1891

  Rubin, Joseph ^a   Gallagher, James G ^b   Schroeder, Georgene ^a   Schutt, Allan J ^a   Dalton, Robert J ^c   Kugler, John W ^d   Morton, Roscoe F ^e   Mailliard, James A ^f   Burch, Patrick A ^a  

^a MAYO CLINIC   (United States)

^b GEISINGER MEDICAL CENTER   (United States)

^c Duluth Community Clinical Oncology Program   (United States)

^d Illinois Oncol Res Assoc CCOP   (United States)

^e Iowa Oncology Research Association CCOP   (United States)

^f CREIGHTON UNIVERSITY   (United States)

Author keywords

5 fluorouracil; gastric carcinoma; leucovorin; pancreatic carcinoma

Indexed keywords

FLUOROURACIL; FOLINIC ACID;

ADULT; ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; PANCREAS CARCINOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; STOMACH CANCER; SURVIVAL RATE; TREATMENT PLANNING;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAUSE OF DEATH; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; STOMACH NEOPLASMS;

EID: 0029808109     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19961101)78:9<1888::AID-CNCR7>3.0.CO;2-B     Document Type: Article

References (20)

1. Kovach JS, Moertel CG, Schutt AJ, Hahn RG, Reitemeier RJ. A controlled study of combined 1,3-bis, (2-choroethyl)-1-nitrosourea and 5-fluorouracil therapy for advanced gastric and pancreatic cancer. Cancer 1974;33:563-7.
2. Moertel CG, Mittelman JA, Bakemeier RF, Engstrom P, Hanley J. Sequential and combination chemotherapy of advanced gastric cancer. Cancer 1976;38:678-82.
3. The Gastrointestinal Tumor Study Group. Phase II-III chemotherapy studies in advanced gastric cancer. Cancer Treat Rep 1979;63:1871-76.
4. The Gastrointestinal Tumor Study Group. A comparative clinical assessment of combination chemotherapy in the management of advanced gastric carcinoma. Cancer 1982; 49:1362-6.
5. The Gastrointestinal Tumor Study Group. Randomized study of combination chemotherapy in unresectable gastric cancer. Cancer 1984;53:13-7.
6. MacDonald JS, Woolley PV, Smythe T, Ueno W, Hoth D, Schein PS. 5-Fluorouracil, Adriamycin and mitomycin C (FAM) combination chemotherapy in the treatment of advanced gastric cancer. Cancer 1979;44:42-7.
7. Lacave A, Wils J, Bleiberg H, Diaz-Rubio E, Duez N, Dalesio O. An EORTC gastrointestinal group phase III evaluation of combinations of Methyl-CCNU, 5-Fluorouracil, and Adriamycin in advanced gastric cancer. J Clin Oncol 1987;5:1387-93.
8. Gastrointestinal Tumor Study Group. Triazinate and platinum efficacy in combination with 5-fluorouracil and doxorubicin: results of a three arm randomized trial in metastatic gastric cancer. J Natl Cancer Inst 1988;80:1011-5.
9. Preusser P, Wilke H, Actermath W, Fink U, Lenaz L, Heinicke A, et al. Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer. J Clin Oncol 1989;7:1310-17.
10. Smith FP, Hoth DF, Levin B, Karlin DA, MacDonald JS, Woolley PV, et al. 5-Fluorouracil, Adriamycin and mitomycin C (FAM) chemotherapy for advanced adenocarcinoma of the pancreas. Cancer 1980;46:2014-8.
11. Gastrointestinal Tumor Study Group. Phase II studies of drug combination in advanced pancreatic carcinoma: fluorouracil plus doxorubicin plus mitomycin C. J Clin Oncol 1986;4:1794-8.
12. Oster MW, Gray R, Panasci L, Perry M. Chemotherapy for advanced pancreatic cancer: a comparison of 5-Fluorouracil, Adriamycin and mitomycin C (FAM) with 5-Fluorouracil, Streptozotocin, and mitomycin C (FSM). Cancer 1986;57:29-33.
13. Cullinan SA, Moertel CG, Fleming TR, Rubin J, Krook JE, Evenson LK, et al. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. JAMA 1985;253:2061-7.
14. Petrelli N, Herrera L, Rustum Y, Burke P, Creaven P, Stulc J, et al. A prospective randomized trial of 5-Fluorouracil versus 5-Fluorouracil and high-dose leucovorin versus 5-Fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol 1987; 5:1559-65.
15. Doroshow JH, Multhauf P, Leong L, Margolin K, Litchfield T, Akman S, et al. Prospective randomized trial comparing fluorouracil versus (vs) fluorouracil and high dose folinic acid (HDFA) for treatment of advanced colorectal cancer. J Clin Oncol 1990;8:495-501.
16. Erlichman C, Fine S, Wong A, Elhakim T. A comparison of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma (MCC). J Clin Oncol 1988;6:469-75.
17. Poon MA, O'Connell MJ, Moertel CG, Wieand HS, Cullinan SA, Everson LK, et al. Biochemical modulation of Fluorouracil: evidence of significant improvement and survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989;7:1407-18.
18. Leichman CG, Fleming TR, Muggia FM, Tangen CM, Ardalan B, Doroshow JH, et al. Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a southwest Oncology Group Study. J Clin Oncol 1995;13:1303-11.
19. Crown J, Casper ES, Botet J, Murray P, Kelssen DP. Lack of efficacy of high dose leucovorin and fluorouracil in patients with advanced pancreatic adenocarcinoma. J Clin Oncol 1991;9:1682-6.
20. DeCaprio J, Mayer RJ, Gronin R, Arbuck SG. Fluorouracil and high dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: results of a phase II trial. J Clin Oncol 1991;9:2128-33.